Healthcare Industry News: antiviral
News Release - February 7, 2011
Alios BioPharma Names Carol L. Brosgart, M.D., as Chief Medical OfficerProminent Bay Area Physician Noted for Work in Hepatitis and HIV
SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - Alios BioPharma, Inc. today announced the appointment of Carol L. Brosgart, M.D., as Chief Medical Officer. In this position, Dr. Brosgart will be responsible for leading the company's clinical drug development programs and will report to Lawrence M. Blatt, Ph.D., Founder and Chief Executive Officer of Alios BioPharma, Inc.
"I have known Carol for several years and we are extremely excited that someone of her caliber and expertise is joining the Alios team at this critical time in our corporate development," said Dr. Blatt. "With her important experience leading the clinical development of successful antiviral programs at Gilead, along with her long track record of clinical focus on virology, Carol will play a critical role in advancing the Alios lead development candidates into Phase I clinical trials. In addition, Carol's deep understanding of clinical trials design in the area of virology should facilitate rapid development of our lead programs in various antiviral clinical indications."
"I am very pleased to join Alios BioPharma at such an exciting stage of its development," said Dr. Brosgart. "Alios has a promising pipeline of antiviral products and is well positioned to achieve its goal of bringing innovative therapeutics to patients."
Dr. Brosgart joins Alios from Children's Hospital & Research Center in Oakland, California, where she served as Senior Vice President and Chief Medical Officer. Previously, she gained more than a decade of pharmaceutical industry experience at Gilead Sciences, Inc., where she held a number of senior management roles, most recently as Vice President, Public Health and Policy and earlier as Vice President, Clinical Research and Vice President, Medical Affairs and Global Medical Director, Hepatitis. During her tenure leading clinical research at Gilead, two antiviral clinical drug development programs -- VireadŽ for the treatment of HIV and HepseraŽ for the treatment of chronic hepatitis B -- were approved by the FDA and regulatory agencies worldwide.
Prior to Gilead, Dr. Brosgart worked for more than 20 years in clinical care, research and teaching at several Bay Area medical centers. Thirty years ago, she was among the first physicians in the country to recognize and treat patients with HIV/AIDS. Among her many accomplishments, Dr. Brosgart directed NIH collaborative research trials as a member of the leadership of the Community Programs for Clinical Research on AIDS and prior to joining Gilead, she contributed to the development of all of the antiretrovirals for HIV and the agents for the prophylaxis and treatment of opportunistic complications of HIV.
Dr. Brosgart received her B.S. in community medicine from the University of California, Berkeley (UCB) and her M.D. from the University of California, San Francisco (UCSF). She completed postgraduate training in pediatrics at UCSF and completed an additional residency in preventive medicine offered by a joint program of the California State Department of Public Health and UCB School of Public Health. She has published extensively in the areas of infectious diseases, focusing on antiviral therapy for CMV, HIV, HBV, and related public health policy.
About Alios BioPharma
Alios BioPharma, Inc., an emerging biotechnology company headquartered in South San Francisco, California, is developing novel medicines to treat viral diseases by activating pathways in the innate immune system. Alios is also developing nucleoside and nucleotide based therapeutics for the treatment of viral diseases including Hepatitis C. For more information: www.aliosbiopharma.com.
Source: Alios BioPharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.